about
Phage therapy: concept to curePhage therapy of Pseudomonas aeruginosa infection in a mouse burn wound modelPhage cocktails and the future of phage therapyImportance of prophages to evolution and virulence of bacterial pathogensStrain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of InfectionApplication of Bacteriophage-containing Aerosol against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii in an Intensive Care UnitComputational models of populations of bacteria and lytic phage.Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii.Classification of 17 newly isolated virulent bacteriophages of Pseudomonas aeruginosa.Stem cell entrepreneurship-trends and advances-IIBacteriophages of Pseudomonas.Experimental phage therapy of burn wound infection: difficult first stepsPhages limit the evolution of bacterial antibiotic resistance in experimental microcosms.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Modeling bacteriophage amplification as a predictive tool for optimized MALDI-TOF MS-based bacterial detection.Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients.Genomic, proteomic and morphological characterization of two novel broad host lytic bacteriophages ΦPD10.3 and ΦPD23.1 infecting pectinolytic Pectobacterium spp. and Dickeya spp.Removal of endotoxins from bacteriophage preparations by extraction with organic solvents.Targeting Enterococcus faecalis biofilms with phage therapy.Enumeration of bacteriophage particles: Comparative analysis of the traditional plaque assay and real-time QPCR- and nanosight-based assaysNovel approaches to developing new antibiotics for bacterial infections.Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung.Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the WestApproaches for reducing Salmonella in pork production.What are the limitations on the wider therapeutic use of phage?Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.Call for a dedicated European legal framework for bacteriophage therapy.Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision MedicineOptimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.Phage approved in food, why not as a therapeutic?Virus interactions: cooperation or competition?Back to the future: bacteriophages as promising therapeutic tools.Genetically modified bacteriophages.Experimental phage therapy against haematogenous multi-drug resistant Staphylococcus aureus pneumonia in mice.Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages.The viability of lytic bacteriophage ΦD5 in potato-associated environments and its effect on Dickeya solani in potato (Solanum tuberosum L.) plants.Stability of bacteriophages in burn wound care products.Unexploited opportunities for phage therapy.The cell lysis activity of the Streptococcus agalactiae bacteriophage B30 endolysin relies on the cysteine, histidine-dependent amidohydrolase/peptidase domain.
P2860
Q21131139-8F1D0A25-84E2-4AC5-B204-5414A35A6D78Q24673374-1A96FDF8-9805-4B69-BD7C-1ADF7455E6DFQ26995797-9FE0A953-5E6E-4925-BA2E-438E421552FEQ28289474-9180E70D-BB9F-449E-968F-A8BB64B0DBB3Q28546694-8AB88A18-26AE-43CE-B6ED-745D4CDE6765Q28555082-B861F704-14EB-4C2C-907B-C8834C3488B0Q30251932-A01A55E2-94EE-4864-B120-6B8F69185C3AQ33567388-642398AE-3903-4241-88E9-82A178905C2DQ33746414-EB6B3ECC-0883-4A2F-BC07-C89CFB8E3B3FQ33979416-0EBBFCB9-64EB-48EB-8AA5-7C88AECA21DDQ34126072-E7AB5AE5-8223-4E62-B537-2B85B6D4ECBDQ34420348-AE555A47-A982-4697-B966-ADC18343D8ABQ34426663-A07CB083-78F9-48BF-AF7B-910A7843433CQ34447679-1C510889-7165-4CE2-804A-C4B1D00926A8Q34475381-34A5E201-4C6B-4EAE-9919-C359FC997F6EQ35130454-6465A78D-231A-4A45-AF71-5C8F898F722BQ35213854-E8F09C5E-B9FC-440E-976D-93CCAEB82530Q35219507-78F77683-30A9-4546-9F39-07147C86F291Q35221145-65B660D1-DDB2-4F96-A3FB-B67F17A33693Q35754471-95208208-09F8-405A-A414-F4F9F8C73486Q36358643-0AAD45E5-FDD5-4030-A464-49ACC74AAB94Q36571855-55579817-1AF8-4065-AF1A-17AF07702AA7Q36891010-B50F0E94-D4F8-4416-B8D1-BE536BE1B0C6Q37017500-D335B260-5310-46F5-9E6D-E094D217B2CFQ37291441-D26992B1-5E8C-4F06-860C-9A7B79BA5004Q37335751-EA974A58-E6C5-4BE0-A900-6B532A705938Q37631618-B62EC41B-E514-44F3-B125-4468210A2BCAQ37644025-3B6677ED-C662-4143-8D48-FBC0AB0BF2D3Q38004869-2DF9DEC9-9739-491C-9296-C4D45FC37F1AQ38214603-69ED9F62-5687-4BC3-8766-EA414B798554Q38285489-CA1B7E6D-79C5-4291-8033-26A9B8E9CBCFQ38672098-9EBF256C-05FF-4913-9250-3AFF49959A55Q38739669-2E03B0BA-197A-4102-8EAA-59719F6EBC20Q38746993-8CF614D2-7A5A-4F9E-9679-4D9CF5315725Q40063304-55B371D0-F19B-4271-8990-9B0090A19D1CQ40093280-18CB035C-CC97-4861-95BA-BDC848BC5B60Q40097098-22C088CB-8BCB-4460-8D66-C9AB368B0F25Q40105662-52C0737A-2332-4603-84F1-BF33F28DF23CQ40964122-46537B4C-6A9D-461E-A36B-6BA1B64FB1FEQ41487168-8169FAAB-E604-44ED-A3E0-24A95EE0FF76
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Old dogma, new tricks--21st Century phage therapy.
@ast
Old dogma, new tricks--21st Century phage therapy.
@en
Old dogma, new tricks--21st Century phage therapy.
@nl
type
label
Old dogma, new tricks--21st Century phage therapy.
@ast
Old dogma, new tricks--21st Century phage therapy.
@en
Old dogma, new tricks--21st Century phage therapy.
@nl
prefLabel
Old dogma, new tricks--21st Century phage therapy.
@ast
Old dogma, new tricks--21st Century phage therapy.
@en
Old dogma, new tricks--21st Century phage therapy.
@nl
P356
P1433
P1476
Old dogma, new tricks--21st Century phage therapy.
@en
P2093
Karl Thiel
P2888
P356
10.1038/NBT0104-31
P577
2004-01-01T00:00:00Z